HER2-Positive Breast Cancer | Clinical

FDA Grants Fast Track Designation for HER2-Positive Metastatic Breast Cancer

January 04, 2021

The FDA granted a Fast Track designation to ARX788 as a single agent for the treatment of patients with advanced or metastatic HER2-positive breast cancer who received at least 1 prior anti-HER2 regimen in the metastatic setting.

FDA Approves Margetuximab Plus Chemotherapy in HER2+ Metastatic Breast Cancer

December 16, 2020

The FDA granted approval to the Fc-engineered, monoclonal antibody margetuximab in combination with chemotherapy, as treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.

Neratinib Plus Capecitabine Improved PFS in Patients With HER2+ Breast Cancer With Brain Mets

December 15, 2020

Neratinib in combination with capecitabine induced a 34% reduction in the risk of disease progression or death as treatment of patients with HER2-positive breast cancer who had central nervous system metastases at baseline compared with lapatinib and capecitabine.

Tucatinib Combo Lengthens Time to Deterioration of HRQoL in HER2+ mBC With Brain Mets

December 12, 2020

Patients with HER2-positive metastatic breast cancer and brain metastases treated with the combination of tucatinib, trastuzumab, and capecitabine had significantly lengthened the time to deterioration of health-related quality of life, according to the results of an analysis of the HER2CLIMB clinical trial presented during the 2020 San Antonio Breast Cancer Symposium.

Better Prediction of Response to Trastuzumab Deruxtecan Analyzed in HER2-Positive Breast Cancer

December 11, 2020

To identify which patients with HER2-positive breast cancer are most likely to respond to fam-trastuzumab deruxtecan-nxki, investigators used a novel HER2 quantitative continuous score to provide a better objective and quantitative assessment of HER2 expression, data presented during the 2020 San Antonio Beast Cancer Symposium show.

Trastuzumab Deruxtecan in DESTINY-Breast01 Demonstrates Continued Efficacy and Safety in HER2+ Metastatic Breast Cancer

December 10, 2020

Patients with HER2-positive metastatic breast cancer treated with fam-trastuzumab deruxtecan-nxki had continued to experience extended durable responses and overall survival rates, along with tolerable toxicity in the phase 2 DESTINY-Breast01 study for which data were presented during the 2020 San Antonio Breast Cancer Symposium.